Treatment of COVID-19 by monoclonal antibodies and the traditional Chinese medicine  

作　　者：Yuyan Ling Yuxuan Dong Qirui Li Doudou Huang Zhihui Li Meijuan Chen 

机构地区：[1]School of Medicine&Holistic Integrative Medicine,Nanjing University of Chinese Medicine,Nanjing,210023,China

出　　处：《Medicine in Novel Technology and Devices》2022年第3期144-147,共4页医学中新技术与新装备（英文）

基　　金：Traditional Chinese and Western Medicine Clinical Medicine Brand Construction Project of Jiangsu Higher Education Institutions(Phase II),No:2020PPZXL261.

摘　　要：The mortality rate of the recent global pandemic corona virus disease 2019(COVID-19)is currently as high as 7%.The SARS-CoV-2 virus is the culprit behind COVID-19.SARS-CoV-2 is an enveloped single-stranded RNA virus,the genome encodes four types of the structural proteins:S protein,E protein(envelope protein),M protein(matrix protein)and N protein(nucleocapsid protein).In COVID-19,monoclonal antibodies have played a significant role in diagnosis and treatment.This article briefly introduced the development of monoclonal antibodies targeting on S protein and N protein,which represents the main direction of monoclonal antibody drugs used in the diagnosis and treatment of COVID-19.Meanwhile,the traditional Chinese medicine also plays important role in the fight against COVID-19 by regulating human immunity.The article introduced the use of traditional Chinese medicine in fighting against COVID-19.

关 键 词：Monoclonal antibody(mAbs) Corona virus disease 2019(COVID-19) S protein N protein Traditional Chinese medicine 

分 类 号：R259[医药卫生—中西医结合]